Edwards Lifesciences Corp
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Stockholders' Equity
| Common Stock · Treasury Stock | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Par Value · Shares · Amount · Additional Paid-in Capital · Retained Earnings · Accumulated Other Comprehensive Loss · Total Edwards Lifesciences Corporation Stockholders' Equity · Noncontrolling Interest · Total Stockholders' Equity | ||||||||||||||||||
| Balance at December 31, 2023 | 650.5 | $650.5 | 49.4 | $(5,024.5) | $2,274.4 | $8,992.4 | $(242.8) | $6,650.0 | $69.4 | $6,719.4 | ||||||||
| Net income | 351.9 | 351.9 | (0.9) | 351.0 | ||||||||||||||
| Other comprehensive gain, net of tax | 9.5 | 9.5 | 9.5 | |||||||||||||||
| Common stock issued under stock plans | 1.3 | 1.3 | 60.8 | 62.1 | 62.1 | |||||||||||||
| Stock-based compensation expense | 44.6 | 44.6 | 44.6 | |||||||||||||||
| Purchases of treasury stock | — | (0.2) | (0.2) | (0.2) | ||||||||||||||
| Balance at March 31, 2024 | 651.8 | $651.8 | 49.4 | $(5,024.7) | $2,379.8 | $9,344.3 | $(233.3) | $7,117.9 | $68.5 | $7,186.4 | ||||||||
| Net income | 366.3 | 366.3 | (1.3) | 365.0 | ||||||||||||||
| Other comprehensive gain, net of tax | 13.1 | 13.1 | 13.1 | |||||||||||||||
| Common stock issued under equity plans | 1.7 | 1.7 | 52.6 | 54.3 | 54.3 | |||||||||||||
| Stock-based compensation expense | 43.9 | 43.9 | 43.9 | |||||||||||||||
| Purchases of treasury stock | 1.8 | (158.1) | (158.1) | (158.1) | ||||||||||||||
| Balance at June 30, 2024 | 653.5 | $653.5 | 51.2 | $(5,182.8) | $2,476.3 | $9,710.6 | $(220.2) | $7,437.4 | $67.2 | $7,504.6 | ||||||||
| Net income | 3,070.8 | 3,070.8 | (1.4) | 3,069.4 | ||||||||||||||
| Other comprehensive loss, net of tax | (32.3) | (32.3) | (32.3) | |||||||||||||||
| Common stock issued under equity plans | 0.8 | 0.8 | 33.7 | 34.5 | 34.5 | |||||||||||||
| Stock-based compensation expense | 42.1 | 42.1 | 42.1 | |||||||||||||||
| Purchases of treasury stock | 13.3 | (906.9) | (100.0) | (1,006.9) | (1,006.9) | |||||||||||||
| Balance at September 30, 2024 | 654.3 | $654.3 | 64.5 | $(6,089.7) | $2,452.1 | $12,781.4 | $(252.5) | $9,545.6 | $65.8 | $9,611.4 | ||||||||
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
| Common Stock · Treasury Stock | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Par Value · Shares · Amount · Additional Paid-in Capital · Retained Earnings · Accumulated Other Comprehensive Loss · Total Edwards Lifesciences, Inc. Stockholders' Equity · Noncontrolling Interest · Total Stockholders' Equity | |||||||||||||||||||
| Balance at December 31, 2022 | 646.3 | $646.3 | 38.0 | $(4,144.0) | $1,969.3 | $7,590.0 | $(254.9) | $5,806.7 | $— | $5,806.7 | |||||||||
| Net income | 340.5 | 340.5 | — | 340.5 | |||||||||||||||
| Other comprehensive loss, net of tax | (0.5) | (0.5) | (0.5) | ||||||||||||||||
| Common stock issued under stock plans | 0.8 | 0.8 | 41.1 | 41.9 | 41.9 | ||||||||||||||
| Stock-based compensation expense | 38.9 | 38.9 | 38.9 | ||||||||||||||||
| Purchases of treasury stock | 3.1 | (249.5) | (249.5) | (249.5) | |||||||||||||||
| Changes to noncontrolling interest | 84.0 | 84.0 | |||||||||||||||||
| Balance at March 31, 2023 | 647.1 | $647.1 | 41.1 | $(4,393.5) | $2,049.3 | $7,930.5 | $(255.4) | $5,978.0 | $84.0 | $6,062.0 | |||||||||
| Net income | 307.1 | 307.1 | (1.6) | 305.5 | |||||||||||||||
| Other comprehensive loss, net of tax | (0.1) | (0.1) | (0.1) | ||||||||||||||||
| Common stock issued under equity plans | 2.0 | 2.0 | 58.8 | 60.8 | 60.8 | ||||||||||||||
| Stock-based compensation expense | 37.4 | 37.4 | 37.4 | ||||||||||||||||
| Purchases of treasury stock | 0.1 | (7.5) | (7.5) | (7.5) | |||||||||||||||
| Changes to noncontrolling interest | (11.6) | (11.6) | |||||||||||||||||
| Balance at June 30, 2023 | 649.1 | $649.1 | 41.2 | $(4,401.0) | $2,145.5 | $8,237.6 | $(255.5) | $6,375.7 | $70.8 | $6,446.5 | |||||||||
| Net income | 384.9 | 384.9 | (1.2) | 383.7 | |||||||||||||||
| Other comprehensive loss, net of tax | 5.4 | 5.4 | 5.4 | ||||||||||||||||
| Common stock issued under equity plans | 0.8 | 0.8 | 33.2 | 34.0 | 34.0 | ||||||||||||||
| Stock-based compensation expense | 32.6 | 32.6 | 32.6 | ||||||||||||||||
| Purchases of treasury stock | 2.2 | (175.1) | (175.1) | (175.1) | |||||||||||||||
| Balance at September 30, 2023 | 649.9 | $649.9 | 43.4 | $(4,576.1) | $2,211.3 | $8,622.5 | $(250.1) | $6,657.5 | $69.6 | $6,727.1 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.